Compositions and methods for modulating farnesoid X receptors

US11021446B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Donatella Chianelli · San Diego, US
• Runyan Li · Shanghai, CN
• Valentina Molteni · San Diego, US
• John Nelson · San Diego, US
• Jason Thomas Roland · San Diego, US
• Paul V. Rucker · Carlsbad, US
• David C. Tully · San Diego, US
• Xiaoyang Wang · Shanghai, CN
• Liladhar Murlidhar Waykole · East Hanover, US
• Yubo ZHANG · Shanghai, CN
• Bo Zhou · Chengdu, CN

Key dates

• Filing date: Apr 21, 2020
• Grant date: Jun 1, 2021
• Expiry date: Apr 21, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D491/052
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds of Formula I, a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesoid X receptors (FXR).